MedTrace Logo

14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man

NCT01176201 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-08-26

No results posted yet for this study

Summary

This is an open-label study to determine the ADME (Absorption, Disposition, Metabolism and Excretion) of 14C labeled SLV337 after a single dose of an oral suspension.

Conditions

  • Healthy Subjects

Interventions

DRUG

SLV337 suspension

400 mg experimental

DRUG

SLV337 capsule

5 x 200 mg immediate release capsule

Sponsors & Collaborators

  • Abbott Products

    lead INDUSTRY

Principal Investigators

  • Anita Vanderlaan · Abbott Healthcare Products BV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01176201 on ClinicalTrials.gov